EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The ahpC c−54t compensatory mutation is not always a valid surrogate for isoniazid resistance in Mycobacterium tuberculosis

Viktória Szél, Jody E Phelan iD, Sophia B Georghiou iD, David L Dolinger, Taane G Clark iD, Stefan Niemann iD, Lilla K Lőrinczi, Claudio U Köser iD

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.00265-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Viktória Szél und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Reference Laboratory for Mycobacteriology, National Koranyi Institute of Pulmonology, Budapest, Hungary. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Isoniazid, Antitubercular Agents, Bacterial Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK Research and Innovation, German Ministry of Health, Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thirteen commercial genotypic antimicrobial susceptibility assays interrogate mutations upstream of ahpC to infer isoniazid resistance for Mycobacterium tuberculosis . We demonstrate that relying on one of these compensatory mutations (i.e., ahpC c−54t)—rather than causative resistance mutations in katG that ahpC compensates for—can result in systematic false-resistant results for isoniazid with the Cepheid Xpert MTB/XDR and suboptimal treatment. The WHO mutation catalog should be refined to address this scenario.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisIsoniazidAntitubercular AgentsBacterial ProteinsMicrobial Sensitivity TestsMutationHumansDrug Resistance, BacterialTuberculosis, Multidrug-ResistantCatalase

Stichwörter der Autor:innen

Cepheid Xpert MTB/XDRMycobacterium tuberculosisahpCgenotypic antimicrobial susceptibility testingisoniazid

Substanzen

IsoniazidAntitubercular AgentsBacterial ProteinskatG protein, Mycobacterium tuberculosisCatalase

Autor:innen und Institutionen

  • National Reference Laboratory for Mycobacteriology, National Koranyi Institute of Pulmonology, Budapest, Hungary.
  • Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom.
  • End TB Dx Consulting LLC, San Diego, California, USA.
  • DLD IVD Consulting LLC, Medway, Massachusetts, USA.
  • Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany.
  • German Center for Infection Research, Partner site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany.

ORCID-Profile: Jody E Phelan, Sophia B Georghiou, Taane G Clark, Stefan Niemann, Claudio U Köser

Förderung

  • UK Research and Innovation
  • German Ministry of Health
  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Szél, V., Phelan, J. E., Georghiou, S. B., Dolinger, D. L., Clark, T. G., Niemann, S., Lőrinczi, L. K., & Köser, C. U. (2025). The ahpC c−54t compensatory mutation is not always a valid surrogate for isoniazid resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00265-25

Vancouver

Szél V, Phelan JE, Georghiou SB, Dolinger DL, Clark TG, Niemann S, et al. The ahpC c−54t compensatory mutation is not always a valid surrogate for isoniazid resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00265-25

BibTeX
@article{Szl2025,
  author = {Szél, Viktória and Phelan, Jody E and Georghiou, Sophia B and Dolinger, David L and Clark, Taane G and Niemann, Stefan and Lőrinczi, Lilla K and Köser, Claudio U},
  title = {The ahpC c−54t compensatory mutation is not always a valid surrogate for isoniazid resistance in Mycobacterium tuberculosis},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.00265-25}
}
Kostenlos starten →